Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that first-time results from three pivotal clinical trials will be presented during late-breaking Presidential ...
Zydus Lifesciences Limited (Zydus), an innovation-led global life-sciences company, and Formycon AG (Formycon), an ...
Zydus Lifesciences announces that the FDA has accepted the BLA for FYB206, a biosimilar to Keytruda. As the patent expiration ...
La dose devra être adaptée à l'intensité de la douleur et à la sensibilité individuelle de chaque patient. La dose antalgique efficace la plus faible doit généralement être choisie. Une dose ...
Indian pharma companies - Read all the latest news headline updates on Indian pharma companies. Get all the Indian pharma companies breaking news updates, videos, photostories and more at Business ...
MSD Korea is bringing a subcutaneous formulation of its blockbuster cancer drug Keytruda to Korea, offering patients and ...
Merck acquires global rights to SciBrunch Therapeutics’ SPR2015, a preclinical oral KRAS G12D inhibitor, in a deal worth up to $2.13 billion.
Merck (MRK) has secured Japanese regulatory approval for KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) for subcutaneous injection, covering all indications currently approved for ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...
A global investigation reveals how the high price of Merck’s blockbuster cancer drug Keytruda locks out patients in lower-income countries.
From today, the Australian government will expand Pharmaceutical Benefits Scheme (PBS) access to the drug Keytruda for three additional types of cancer. This is part of a broader shift away from ...
From today, the Australian government will expand Pharmaceutical Benefit Scheme (PBS) access to the drug Keytruda for three additional types of cancer. These three conditions will be covered as part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results